Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01262586
- Locations
- π©πͺ
Novartis Investigative Site, Mainz, Germany
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
Phase 3
Terminated
- Conditions
- Cardiovascular Events
- Interventions
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2336
- Registration Number
- NCT01259297
- Locations
- πΈπͺ
Novartis Investigative Site, Stockholm, Sweden
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Phase 3
Completed
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 725
- Registration Number
- NCT01259492
- Locations
- πΈπͺ
Novartis Investigative Site, Stockholm, Sweden
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 111
- Registration Number
- NCT01257815
- Locations
- π¬π§
Novartis Investigative Site, York, United Kingdom
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 431
- Registration Number
- NCT01257451
- Locations
- π¬π§
Novartis Investigative Site, Wiltshire, United Kingdom
Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection
Phase 4
Withdrawn
- Conditions
- Upper Respiratory Tract Infections
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2012-04-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01257126
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
Phase 2
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 341
- Registration Number
- NCT01256411
- Locations
- πΉπ
Novartis Investigative Site, Chiang Mai, Thailand
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
Phase 1
Completed
- Conditions
- Advanced Age-related Macular Degeneration
- Interventions
- Biological: LFG316
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01255462
- Locations
- πΊπΈ
Retina Consultants of Houston, Houston, Texas, United States
πΊπΈNational Ophthalmic Research Institute, Fort Myers, Florida, United States
πΊπΈTexas Retina Associates, Dallas, Texas, United States
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 421
- Registration Number
- NCT01254188
- Locations
- π¦πͺ
Novartis Investigative Site, Dubai, United Arab Emirates
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01254227
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath